Literature DB >> 12970798

Thalidomide therapy induces response in relapsed mantle cell lymphoma.

G Damaj, F Lefrère, R Delarue, B Varet, R Furman, O Hermine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12970798     DOI： 10.1038/sj.leu.2403058

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition.

Authors:  Guoqiang Xu; Xiaogang Jiang; Samie R Jaffrey
Journal:  J Biol Chem       Date:  2013-08-27       Impact factor: 5.157

Review 2.  Management of mantle cell lymphoma in the elderly: current and potential strategies.

Authors:  Marguerite Vignon; Marie-Dominique Venon; Olivier Hermine; Richard Delarue
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

3.  Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma.

Authors:  Kai Song; Brett H Herzog; Minjia Sheng; Jianxin Fu; J Michael McDaniel; Hong Chen; Jia Ruan; Lijun Xia
Journal:  Cancer Res       Date:  2013-10-24       Impact factor: 12.701

Review 4.  Cereblon: promise and challenges for combating human diseases.

Authors:  Hyoung Kyu Kim; Jung Eun Seol; Sang Woo Ahn; Seungje Jeon; Chul-Seung Park; Jin Han
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 3.657

Review 5.  Cereblon in health and disease.

Authors:  Hyoung Kyu Kim; Tae Hee Ko; Bayalagmaa Nyamaa; Sung Ryul Lee; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Chul-Seung Park; Bernd Nilius; Jin Han
Journal:  Pflugers Arch       Date:  2016-06-24       Impact factor: 3.657

6.  Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases.

Authors:  Hongyang Wu; Chenchen Zhao; Kangsheng Gu; Yang Jiao; Jiqing Hao; Guoping Sun
Journal:  Mol Clin Oncol       Date:  2014-06-06

Review 7.  Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective.

Authors:  Madhav Desai; Kate Newberry; Zhishuo Ou; Michael Wang; Liang Zhang
Journal:  Ther Adv Hematol       Date:  2014-06

Review 8.  Therapeutic effects of thalidomide in hematologic disorders: a review.

Authors:  Miao Xu; Yu Hou; Lei Sheng; Jun Peng
Journal:  Front Med       Date:  2013-07-15       Impact factor: 9.927

Review 9.  Management of Drug Resistance in Mantle Cell Lymphoma.

Authors:  Gaël Roué; Brigitte Sola
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.